Pfizer Inc.· @pfizer · X·· 2026-06-07精选AI 评分62
AI 导读
辉瑞公布其在研GLP-1 RA肽的2b期数据，显示每周和每月给药方案均具有稳健疗效和良好的胃肠道耐受性。该结果支持其后续大规模关键性临床项目推进。
推荐理由
辉瑞公布在研GLP-1 RA肽2b期数据，读者可了解其每周与每月给药方案的疗效与胃肠道耐受性表现。
正文
Pfizer is advancing obesity science. New Phase 2b data for our investigational GLP‑1 RA peptide show robust efficacy and favourable GI tolerability across weekly and monthly dosing, supporting our extensive pivotal program.
Learn more: [link]
#ADASciSessions #Obesity #GLP1 #ClinicalTrials #Innovation #Healthcare
来源：Pfizer Inc. · x.com